Wednesday, January 19, 2022
Home Blog

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721 to $0.3500. Shares of BEVVF surged over 63.51% in the last month; with average volume for the month over 186.23K shares. If we look at three-month performance, BEVVF stock gains over 57.16% while average volume for the stock was 99.73K.

Last 12 months have been good for BEVVF with over 4.29% gain in stock price, reaching a high of $0.3800 with a $38.26M market cap. BEVVF stock leapt after collaboration effort to explore multiple opportunities.

What open doors BEVVF has been investigating?

Bee Vectoring Technologies is an agribusiness innovation organization and is a market disruptor with a huge worldwide market an open door in the $240 billion yield assurance and manure market. BEVVF has spearheaded a characteristic accuracy agribusiness framework that replaces substance pesticides and inefficient plant insurance item splash applications by conveying natural pesticide options in contrast to crops utilizing economically developed honey bees.

At present, BEVVF has north of 65 conceded licenses, more than 35 licenses forthcoming in all major rural nations around the world, and has US EPA enlistment of its Vectorite with CR-7 available to be purchased as an enrolled natural fungicide for use on the marked harvests. Bee Vectoring Technologies and BioSafe Systems, LLC (“BioSafe”) on Wednesday mutually declared they have marked a Memorandum of Understanding (MOU).

  • Compliant with the MOU, the organizations have consented to go into itemized conversations on numerous business association extends that call upon one another’s ability.
  • BioSafe and BEVVF are the two innovators in the agrarian biologicals industry with a comparable client base, and proposition administrations and items that are corresponding to each other.
  • The ventures will empower the two organizations to extend each other’s item contributions, markets, and client base.
  • Open doors incorporate matching BioSafe biologicals with BEVVF’s honey bee vectoring framework, and utilizing BEVVF’s Clonostachys rosea CR-7 (CR-7) strain for non-honey bee vectoring applications.
  • Explicit arrangements around there will trail assessments and more point by point conversations based on business conditions.

How BEVVF will be profiting from this course of action?

Bee Vectoring Technologies (BEVVF) considers the MOU to be the debut courses of action with an industry accomplice that is an innovator in natural items. The system of BEVVF is to fabricate organizations with set up accomplices to speed up its development and expand its client reach. Consequently, having the option to draw in the consideration of an industry chief, for example, BioSafe approves that BEVVF innovation is acquiring energy among producers and on the lookout. BioSafe’s multi-market and multi-channel center will assist BEVVF with speeding up development and boost investor esteem.

Best cannabis stock investment could lead to great profits in the near future

LGVN Stock
LGVN Stock

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal, and almost all of them allow medical marijuana. It is important to determine which cannabis stocks offer investors the most potential for returns.

How do cannabis stocks benefit investors?

The cannabis industry is expected to thrive globally with the United States currently being the largest market. In 2025, Investopedia predicts the best cannabis stocks will be worth $30 billion.

According to figures from Cannabiz Media, the US cannabis industry will reach $160.7 billion by 2025. But the fact is that marijuana market is mushrooming regardless of the numbers.

How can you make the most of this information?

The cannabis industry offers a variety of revenue-generating opportunities due to its wide variety of revenue streams. Below you’ll find best cannabis stocksyou might be interested in before it’s too late.

HEXO Corp. (HEXO)’s stock price was $0.67 at the previous market close, with its latest volume reaching 6.25 million. Compare that to its average daily volume of 10.12M. Given the fact that this stock has 355.76M shares outstanding, its current market value is sitting at $0.65.

The Williams Percent Range or Williams %R is a well-known specialized pointer made by Larry Williams to help recognize overbought and oversold circumstances. HEXO Corp. (NASDAQ:HEXO)’s Williams Percent Range or Williams %R at the time of writing to be seated at 91.19% for 9-Day. It is also calculated for different time spans. Currently for this organization, Williams %R is stood at 95.55% for 14-Day, 97.16% for 20-Day, 99.21% for 50-Day and to be seated 99.65% for 100-Day. Relative Strength Index, or RSI(14), which is a technical analysis gauge, also used to measure momentum on a scale of zero to 100 for overbought and oversold. In the case of HEXO Corp., the RSI reading has hit 28.54 for 14-Day.

GrowGeneration Corp. (NASDAQ: GRWG) is currently trading at around $11.12, a price level that means its value has jumped 1.09% higher than its 52-week low. In intraday trading, GRWG shares have hit a high of $11.32 and a low of $10.63. The last 52 weeks have seen the company’s shares touched a high of $67.75 and a low of $11.00, while recent trading session has witnessed an intraday change of just -0.36%.

Although the stock has performed remarkably well in recent months, the overall interest from investors has dropped noticeably. That has seen its trading volume surge by 19.47%, figures that rank poorly compared to the stock’s average volumes. This information is critical as it reflects the stocks’ float size, given that the market is exposed to 51.56 million shares of the company.

Sundial Growers Inc. (NASDAQ:SNDL) does about 112.26M shares in volume on a normal day but saw 96.9 million shares change hands in Monday trading. The company now has a market cap of $1.18 billion. Its current market price is $0.59, marking a decrease of -1.75% compared to the previous close of $0.60. The 52 week high reached by this stock is $3.96 whilst the lowest price level in 52 weeks is $0.50. The script in recent trading has seen the stock touch a high of $0.6097 and a low of $0.5751.

Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Currently at 0.04 is the 14-day ATR for Sundial Growers Inc. (SNDL). The highest level of 52-weeks price has $3.96 and $0.50 for 52 weeks lowest level.

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.


Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading session.  Stealth BioTherapeutics is a clinical-stage biotechnology firm dedicated to the research, development, and marketing of innovative medicines for mitochondrial illnesses. Mitochondria are the body’s principal source of energy generation and are essential for appropriate organ function.

MITO stock’ Recent Development

On Dec 20, 2021 Stealth BioTherapeutics provided information on its Duchenne muscular dystrophy (DMD) research programme following a pre-IND meeting with the FDA’s Division of Cardiology and Nephrology (DCN). It also entails reaching agreement on Stealth’s proposal to use myocardial fibrosis progression as a surrogate endpoint in a clinical study.

The pre-investigational new drug (IND) meeting was held to examine Stealth’s projected DMD development strategy. DCN agreed that cardiac fibrosis measured with late gadolinium enhancement (LGE) on magnetic resonance imaging (MRI) may be used as a main endpoint in Stealth’s planned new clinical study. DCN also described the processes that would be required for an Accelerated Approval based on this outcome if it is determined that slowing fibrosis progression is reasonably expected to result in therapeutic benefit in DMD.

DCN said that the clinical study design was in line with various critical features, while urging that further information be presented with Stealth’s anticipated IND on others. Stealth intends to meet with DCN again early next year as it progresses toward submitting an IND in the first part of the year and perhaps starting a study in the second half of the year, depending on regulatory comments and funding.


New preclinical evidence from Stealth has shown that combining elamipretide with an exon-skipping phosphorodiamidate morpholino oligomer (PMO) dramatically enhances dystrophin expression levels in the X-linked muscular dystrophy (mdx) mouse model. PMO is a medicinal class that has previously been approved by the FDA and commercialised for its effects on skeletal muscle.

CNFinance Holdings Ltd. (CNF) stock fell during after-hours, despite any current update.

LGVN Stock
LGVN Stock

CNFinance Holdings Ltd. (NASDAQ: CNF) stock declined by 20.27% in the after-hours trading session. CNFinance Holdings Limited is a significant provider of home equity loans in China. CNFinance works with sales partners and trust firm partners to do business.

CNF stock’ Recent Past Development

Almost a month ago, CNFinance Holdings announced its financial results for the third quarter of 2021.

  • For Q3 2021, total loan origination volume was RMB3,117.5 million (US$480.7 million), whereas it was RMB3,093.4 million in the same period of 2020.
  • As of September 30, 2021, the total outstanding loan principle was RMB11.1 billion (US$1.7 billion), up from RMB9.7 billion as of December 31, 2020.
  • For Q3 2021, the total interest and fees income was calculated as 0 million (US$70.5 million), down from RMB476.0 million in the same period of 2020.
  • In the third quarter of 2021, net income was RMB19.0 million (US$2.9 million), down from RMB50.1 million in the same period of 2020.
  • For the third quarter of 2021, basic and diluted earnings per ADS were RMB0.28 (US$0.04) and RMB0.25 (US$0.04), respectively, compared to RMB0.73 and RMB0.67, respectively, in the same period of 2020.

Mr. Bin Zhai, CEO and Chairman of CNFinance stated that,

The loan facilitation business held steady in the third quarter of 2021, following a strong first half. The strong business activities of micro- and small-enterprises (MSEs) led to a rise in capital requirements in the third quarter. To satisfy this demand, the skilled and devoted team handled over 5,000 borrowers using their quick and visually appealing online system.

Future Outlook

The amount to which the COVID-19 outbreak affects the Firm’s performance of the business will be determined by future developments of the pandemic in China and across the world, which are unpredictable and susceptible to change. Based on facts known as of the date of this news release, the Company plans to dispose of some non-performing loans in the fourth quarter of 2021 to strengthen the overall loan portfolio, with a net loss of between RMB80 million and RMB100 million.

CalAmp Inc. (CAMP) stock declines in pre-market following its financial earnings.


CalAmp Inc. (NASDAQ: CAMP) stock gained by 5.32% at last close whereas the CAMP stock price declines by 15.07% in the pre-market trading session. CalAmp is a linked intelligence start-up that makes it easier for people and organizations to work together more effectively. They work with companies in the transport and logistics, industrial equipment, government, and automotive industries to provide data that helps them make better decisions.

CAMP stock’ Financial Highlights

CalAmp announced its financial results for the Q3 of the fiscal year 2022. Given below are the highlights:

  • The company reported its net revenue as $69M, it is a decline of 12% from the previous quarter.
  • For the Q3 fiscal year 2022, the sales to their largest customer totaled $14M, up 3% from the previous quarter.
  • In the 3rd quarter of the fiscal year 2022, the gross margin was 41 percent whereas it was 40 percent in the previous quarter.
  • GAAP net loss from continuing operations was $11 mln in the third quarter of fiscal 2022 or a loss of $0.30 per share.
  • Non-GAAP net loss was $3 million, or $0.08 per diluted share, on an adjusted basis.
  • Adjusted EBITDA was $3 million, or 4% of revenue, relative to $9 mln, or 11% of revenue, in the previous quarter.
  • Including the Automotive Vehicle Finance division, total core S&SS members were 1 million, up 3% from the previous quarter.
  • Cash and cash equivalents were $91 million at the end of the quarter.

CalAmp’s president and CEO, Jeff Gardner, said that,

The continued worldwide component shortfalls have been more apparent than predicted, resulting in a considerable decline in their shipments throughout the quarter, as stated in the business update released last month. They’re working directly with their suppliers to find the parts they need, certify new components, and, in certain cases, redesign particular devices. Despite this difficult scenario, they are encouraged by robust customer demand, as indicated by the consistently high level of customer backlog over the last few quarters as they continue their transformation to a SaaS company.

Future outlook

The Company will continue to refrain from issuing quarterly guidance. Due to worldwide component supply difficulties and the date of Chinese New Year in February, insight into product shipments is unpredictable.

You can make the most of your finances with these best lithium stocks


Battery manufacturers use lithium as their primary ingredient. Green energy sources have grown in importance in recent years. Lithium is not a new material used in portable electronic devices. Also, lithium is used to develop electric vehicle batteries, whose production has increased substantially since its introduction. For investors, this creates an interesting investment opportunity.

Lithium is becoming increasingly popular among investors. By 2030, Obama wants 80% of America’s electricity to come from renewable sources. The best lithium stocks will benefit as a result of the growth of lithium mines and production firms.

Almost all battery-powered energy solutions use lithium compounds. Currently, the U.S. Geological Survey estimates that over 70% of lithium produced worldwide is used for battery manufacturing. Listed below are the three best lithium stocks to invest in.

Piedmont Lithium Inc. (NASDAQ: PLL) is 100.68% higher on its value in year-to-date trading and has touched a low of $25.36 and a high of $88.97 in the current 52-week trading range. The PLL stock was last observed hovering at around $53.28 in the last trading session, with the day’s gain setting it 4.14% off its average median price target of $87.00 for the next 12 months.

DA Davidson rated the Piedmont Lithium Inc. (NASDAQ: PLL) stock “a Buy”. DA Davidson’s estimates were contained in a research note released on Friday, July 23, 2021. Several other experts on Wall Street have posted such reports regarding the PLL shares. According to Clarksons Platou, the stock is “a Buy,”$86. Clarksons Platou published their figures in a research note released to investors on Wednesday, May 05, 2021. Other experts at JP Morgan have the stock’s price target at $86 price; with their rating of the stock is “an Overweight.”. These scores were published in a research note the firm released on Tuesday, May 04, 2021.

Lithium Americas Corp. (LAC) started the day trading at $29.24 and recorded an intraday high of $29.275. It also recorded an intraday low of $27.99 during Tuesday’s trading session. Lithium Americas Corp. is a very active stock that recorded a trading volume that is more than 42.47% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 2.72 million, which is more than 42.47% of the total average daily trading volume of 2.72 million.

Multiple groups of Wall Street analysts have recently been drawn to the lac stock, with those at Deutsche Bank Downgrade the stock to “a Hold”. The analysts released their assessment via a research note they published on November 16, 2021. Over at Piper Sandler, the analysts restated the earlier stance about Lithium Americas Corp. shares, rating the shares “a Neutral.” in a note released October 01, 2021.

Albemarle Corporation (NYSE: ALB) started the day on 12/21/21, with a price increase of 2.76% at $224.15. During the day, the stock rose to $225.00 and sunk to $219.77 before settling in for the price of $224.15 at the close. Taking a more long-term approach, ALB posted a 52-week range of $133.82-$291.48.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 15, 2021, when Goldman Downgrade the stock to “a Sell” and issued a price target of between $199 and $205. RBC Capital Mkts Upgrade its price target at 246-280.

Sentage Holdings Inc. (SNTG) stock soars during pre-market, Here’s the update

ORCL Stock
ORCL Stock

Sentage Holdings Inc. (NASDAQ: SNTG) stock gained by 5.84% at last close while the SNTG stock price shines during pre-market by 4.14%. Sentage Holdings is a financial services company based in Shanghai, China. It provides a wide variety of financial services.

SNTG stock’ Financial Highlights

Sentage Holdings released financial results for the first half of the fiscal year 2021, which concluded on June 30, 2021. The following is a list of such financial outcomes.

  • Total operational revenue was $1.32 million in the six months ending June 30, 2021, down from $1.73 million in the first six months of the fiscal year 2020, a decline of 24.0 percent. The fall is mostly due to a reduction in the number of outstanding service agreements in the consumer loan repayment and collection management business, which is offset by increasing income from the loan recommendation and prepaid payment network services businesses.
  • In the six months ended June 30, 2021, net income was $0.45 million, opposed to $0.73 million the previous year.
  • In the six months ended June 30, 2021, basic and diluted profits per share were $0.04, opposed to $0.07 the previous year.

Impact of COVID

The current COVID-19 epidemic has had and is likely to have an impact on their business operations. COVID-19 had a transitory effect on the operating results and financial results in the fiscal year 2020 and the six months ending June 30, 2021. However, the revival of COVID-19, as well as the ongoing uncertainty surrounding it, may have a damaging effect on future revenue and cash flows. Economic downturns and other substantial shifts in regional and global economic conditions might result from a COVID-19 comeback. The COVID-19 may also wreak havoc on the real estate market in Shanghai as well as the first cities they’re targeting. It will also reduce the overall loan amount borrowers may get through our services, lowering their service fees, which are dependent on the precise loan amount in each case, and negatively harming our loan recommendation business income.

Salem Media Group Inc. (SALM) stock shines during pre-market, following some changes in management.

INFI Stock
INFI Stock

Salem Media Group Inc. (NASDAQ: SALM) stock gained by 0.36% at last close while the SALM stock price surges by 1.79% in the pre-market trading. Salem Media Group is USA’s premier multimedia corporation specializing in Christian and conservative programming, with radio, internet media, and book and newsletter publishing as well as other media holdings.

SALM stock’ Update

Edward G. Atsinger III who is the CEO of the company will shift to the newly formed job of Executive Chairman of the Board of Directors on January 1, 2022.  In addition, David Santrella has been named Chief Executive Officer by the company’s Board of Directors. Mr. Santrella is the company’s President of Broadcast Media at the moment. Furthermore, Salem’s existing President of Digital Media and Publishing, David Evans, will be elevated to Chief Operating Officer.

Finally, beginning January 1, 2022, Stuart W. Epperson, Salem’s current Chairman, will leave from the Board of Directors and move to Chairman Emeritus, with Stuart W. Epperson, Jr. joining the Board of Directors to fill the void left by Mr. Epperson Senior’s resignation. These adjustments reflect the Board’s continuing succession planning and are intended to ensure leadership continuity as the firm pursues its strategic goals.

Atsinger’s Contributions

Mr. Atsinger and his brother-in-law Mr. Epperson founded Salem in 1974, and since then, the firm has evolved from a tiny radio station to America’s premier multimedia corporation focusing in Christian and conservative material. He’s been a motivating force behind Salem’s objective to provide material to the Company’s viewers around the country that isn’t available through traditional media. Mr. Atsinger will serve as Executive Chairman and Chairman of the Board, leading the board of directors and providing supervision and advice to both the CEO and COO.

Mr. Atsinger stated that,

He is honored to contribute as Executive Chairman and to supervise the company’s leadership transition to the next generation. He is excited to work with the management team to ensure that Salem’s crucial goal of servicing the media requirements of viewers interested in Christian content and public policy programs with a traditional conservative perspective remains.

Rockley Photonics Holdings (RKLY) stock dropped as they discontinue technical sales to Hengtong Rockley Technology.

RKLY Stock
RKLY Stock

Rockley Photonics Holdings. (NASDAQ: RKLY) stock gained by 0.96% at the last close whereas the RKLY stock price fell by 18.56% in the after-hours trading session. Rockley Photonics is an international pioneer in photonics-based health monitoring and communications systems. It is creating a wide range of photonic integrated circuits, sensors, and full-stack solutions.

RKLY stock’ Current Update

Under the current conditions, Rockley Photonics has decided not to continue with its data-communications-related technical sale to Hengtong Rockley Technology. It is a partnership with Jiangsu Hengtong Optic-Electric. As an outcome, Rockley upgraded its business expectation for the entire fiscal year of 2021 and 2022. The deal was canceled because the US Department of Commerce’s Bureau of Industry and Security (BIS) placed Hengtong and some of its affiliates on the BIS “Entity List” with an effective date of December 17, 2021. This implies that corporations cannot provide products or technology to groups on the “Entity List” without prior authorization under the US Export Administration Regulations (EAR). The Company is presently analyzing its relationship with the JV and will make necessary choices based on what it discovers.

Andrew Rickman, founder, and CEO of Rockley stated that,

The creation and marketing of their sensing technology in the health monitoring arena has been and remains to be Rockley’s key emphasis. As detailed in their latest customer and technology developments, they continue to make exceptional progress in this area, and their outlook for this company remains positive. The technical sale to the JV was designed to be a cost-effective strategy for Rockley to commercialize its revolutionary data communications technology while remaining focused on its health and wellness offerings.

He further added,

They continue to completely comply with the rules, and they have chosen not to continue with their technical sale to the JV under the current conditions.  As a result of the BIS action, they will have to change their monetization plan for their communications technology. While they are upset with the immediate impact on their business, they feel that this move will be beneficial to Rockley in the long run. However, since these solutions were not critical to the future development possibilities, they will have no impact on the company’s long-term prospects.

Aldeyra Therapeutics Inc. (ALDX) stock declines during after-hours. Here’s what’s happening

ALDX Stock
ALDX Stock

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) stock gained by 1.28% at the last close whereas the ALDX stock price plunge by 36.33% in the after-hours trading session. Aldeyra Therapeutics is a biotechnology business dedicated to the development of innovative immune-modulating treatments for the treatment of ocular and systemic disorders.

ALDX stock’ Current Update

Aldeyra Therapeutics released important findings from the 0.25 percent reproxalap ophthalmic solution Phase 3 TRANQUILITY Trial. It’s a potential treatment for an experimental medication to control dry eye conditions.

Although the primary aim of ocular redness was not fulfilled in TRANQUILITY, the dry eye disease symptom of the Schirmer test, a secondary endpoint, attained statistical power (p=0.0001). The post-hoc analysis of Schirmer test responders of less than 10 mm also yielded statistical significance (p0.0001). The Schirmer test has been acknowledged as part of the foundation for approval of additional dry eye disease medicines by the US Food and Drug Administration. The primary endpoint of the planned Phase 3 TRANQUILITY-2 Trial has been changed so that it will be fulfilled if the Schirmer test or ocular redness show statistical significance. TRANQUILITY-2’s goal enrolment has now been expanded from 300 to up to 400 patients.


The dry eye disease NDA filing is scheduled in mid-2022, given the enrolment in the current 12-month safety study in dry eye disease individuals and the result of TRANQUILITY-2. Upon the dry eye disease submission and the fulfillment of an additional allergen chamber study required by the FDA, an NDA for allergic conjunctivitis is planned to be submitted. Phase 3 ALLEVIATE conjunctival allergen challenge study and Phase 3 INVIGORATE allergen chamber trial both met primary and major secondary objectives in allergic conjunctivitis.

In TRANQUILITY, no safety signals were seen, and reproxalap was well accepted; no hurdle related to treatment discontinuations or severe or major side events were reported. Over 1,500 patients have already been tested with Reproxalap. Mild and temporary instillation site soreness is the most commonly reported side event.




Download Free eBook For


100% free. stop anytime no spam